Congenital heart diseases (CHD), cleft lip and cleft palate (CLP) comprise the highest incidence of birth defects in the world. The results of epidemiological investigation show a rising incidence of CHD and CLP year by year.^[@R1],[@R2]^ Congenital heart diseases include ventricular septal defect, atrial septal defect, tetralogy of Fallot (TOF), and so on. Tetralogy of Fallot consist of pulmonary artery stenosis, ventricular septal communication, rightward deviation of the aorta\'s origin, and hypertrophy of the right ventricle. However, due to the complex and long cycle of treatment procedures for CHD and CLP, these diseases can bring a heavy burden to family and society and seriously affect neonatal health. The high heritability of CHD, estimated to be between 0.6 and 0.7, suggests a strong genetic component and numerous genes, which have been linked to syndromic and nonsyndromic forms of CHD.^[@R3]^ Together, the above factors drive the need to identify the disease genes responsible for CHD with CLP.

Many genes have been implicated in the development of congenital heart disease or cleft lip and palate. With the rapid development of technology, many methods also had been used to find these disease genes, such as Array-SNP, CNVs, targeted, next-generation sequencing, and whole exome sequencing. Targeted, next-generation sequencing rapidly analyzes large amounts of genetic information. In this paper, we wanted to find disease genes through targeted next-generation sequencing.

METHODS
=======

Patient
-------

The study protocol was approved by the Review Board at Second Xiangya Hospital of Central South University (China), and the related study subject gave informed consent. All experiments were performed in accordance with relevant guidelines and regulations. We enrolled a patient in whom we observed cardiac structure, leading to diagnosis of TOF and CLP by transthoracic echocardiogram.

DNA Extraction
--------------

Genomic DNA was extracted from peripheral blood lymphocytes of the patient. Genomic DNA was prepared for testing by DNeasy Blood and TissueKit (Qiagen, Valencia, CA) on the QIAcube automated DNA-extraction robot (Qiagen, Hilden, Germany), as previously described.^[@R4]^ The quality and quantity of the DNA sample were measured by the use of the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific Inc, Waltham, MA), from which 3 μg of DNA of each sample was used for analysis.

Targeted Next-Generation Sequencing
-----------------------------------

Targeted, next-generation sequencing (NGS), including library construction, capture, and sequencing, was carried out at Oxford Gene Technologies (Oxford, UK). Enrichment of target regions and library preparation were performed by the use of a SureSelectXT2 Custom kit (1--499 kb, 16) in accordance with SureSelect protocol (version 1.2; Agilent Technologies, Changsha, China). Library concentrations were determined using Agilent\'s QPCR NGS Library Quantification Kit (G4880A), with each sample at a final concentration of 10 nmol/L. A HiSeq2000 sequencer ordered the samples using TruSeq chemistry and protocols (version 3, Illumina Inc, San Diego, CA). The TOF with CLP patient was analyzed separately using all CHD or CLP patients grouped into 1 enrichment kit and sequencing run.^[@R3]^

Data Analysis and Filtering
---------------------------

The preliminary data analyses, including read alignment, variant calling, and annotation, were carried out by Oxford Gene Technologies. All variants that affect protein-coding regions for each sample were categorized into "novel" and "known" categories according to their presence in Single-Nucleotide Polymorphism Database (dbSNP) 137. Minor allele frequencies of all known variants were reported according to Exome Sequencing Project (ESP) or Yan Huang (YH), 1000 Genomes Project (TGP) if not present in dbSNP137. All variants were subjected to in silico analysis, which included prediction programs, such as SIFT, PolyPhen-2, and Mutation Taster.

Variant Validation
------------------

Variants warranting further investigation included novel variants, which were predicted to be "probably damaging," "disease causing," or "damaging," according to PolyPhen-2, mutation tasting, and SIFT predictions, or these variants were known to be "probably damaging" and possessed minor allele frequencies \<0.1%. Variants were verified by Sanger sequencing. To confirm the related disease genes, we surveyed the relevant literature on PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>).

Polymerase Chain Reaction
-------------------------

Entire exons and exon--intron junctions of *MTHFR* (Refseq:NM_005957) were amplified by polymerase chain reaction (PCR, primer sequences will be provided upon request). Sequences of the PCR products were determined using an ABI 3100Genetic Analyzer. The primer sequences are as follows:

Forward primer: 5′ ATAGGTGACCAGTGGGAAGA 3′,

Reverse primer: 5′ CTGATCACTGTGTCCTGAACC 3′.

RESULTS
=======

In our study, there were 1390 SNPs and 130 indels mutations (a total of 1520 mutations) that successfully passed the filtering criteria as identified by targeted, next-generation sequencing. In addition, there were 6 gene mutations (*ZNF528*, *PVRL2*, methylenetetrahydrofolate reductase \[*MTHFR*\], *EVC2*, *DAND5*, consensus coding sequence \[*CCDC39*\]) not found in the databases used, such as dbSNP, YH, ESP, and TGP (Table [1](#T1){ref-type="table"}).

Four genes (*ZNF528, PVRL2, EVC2, CCDC39*) were all predicted to be "tolerated," "benign," and/or "polymorphic" by SIFT, PolyPhen-2, and Mutation Taster. The *DAND5* gene was predicted to be "possibly damaging" and "disease causing" respectively by PolyPhen-2 and Mutation Taster, but the SIFT program predicted this mutation to be "tolerated." The *MTHFR* gene mutation was predicted to be "damaging," "possibly damaging," and "disease causing" respectively by SIFT, PolyPhen-2, and Mutation Taster (Table [2](#T2){ref-type="table"}). At last, we verified the variant by Sanger sequencing (Fig. [1](#F1){ref-type="fig"}). There is no relevant report about *MTHFR* gene mutation (c.G586A, p.G196S) on PubMed.

![The results of prediction programs. (A) Mutation Taster prediction. (B) SIFT prediction. (C) Polyphen-2 prediction. (D) The results of Sanger sequencing.](jcrsu-28-e351-g001){#F1}

DISCUSSION
==========

With the rapid development of technology, many methods had been used to find the disease-causing genes, such as Array-SNP, CNVs, targeted, next-generation sequencing, and whole exome sequencing. Targeted, next-generation sequencing offers opportunities for genetic testing and can analyze large amounts of genetic information rapidly. We consider targeted, next-generation sequencing to be more clinically useful than whole exome sequencing, due to speeder turnaround time (reduced sequencing volume and associated data analysis), higher and more reliable coverage, plus the ability to avoid incidental findings.^[@R3]^ In the last few years, many researchers have published reports on gene mutations, discovered by targeted sequencing, for many genetic diseases, including CHD and CL/P.

In this study, a total of 1520 mutations were successfully found in the patient via the targeted, next-generation sequencing. However, there were 6 genes (*ZNF528, PVRL2, MTHFR, EVC2, DAND5, CCDC39*) with mutations not found in existing databases, such as dbSNP, YH, ESP, and TGP. We predicted character of the named gene mutations through PolyPhen-2, SIFT, and Mutation Taster programs. The *ZNF528, PVRL2, EVC2, CCDC39* genes were all predicted to be "tolerated," "benign," and "polymorphic" respectively by SIFT, PolyPhen-2, and Mutation Taster. Thus, we can eliminate those genes mutations. The *DAND5* gene was predicted to be "possibly damaging" and "disease causing," respectively by PolyPhen-2 and Mutation Taster, while the SIFT program predicted *DAND5* to be "tolerated." However, there is a close relationship between the said gene and spiradenoma according to our survey of published reports. The *MTHFR* gene mutation (c.G586A, p.G196S) was predicted to be "damaging," "possibly damaging," and "disease causing" in turn, by SIFT, PolyPhen-2, and Mutation Taster. These predictions support the notion that the *MTHFR* gene variant may contribute to TOF and CLP pathogenesis. We also studied the subject\'s parents using Sanger sequencing, but the results were meaningless. The result should be further verified through a model organism, such as zebra fish or mouse.

The human *MTHFR* gene, consisting of 11 exons, catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for the remethylation of homocysteine to methionine, which plays a key role in neural tube and vascular defects during embryogenesis.^[@R5]^ According to the Human Gene Mutation Database, 74 mutations on the *MTHFR* gene have been reported in several congenital heart diseases. So far, more than 8 genes (*JAG1, NKX2--5, GATA4, MTHFR, ZFPM2, GDF1, TBX1, GATA6*) have been implicated in TOF.^[@R6]--[@R11]^ Moreover, more than 12 genes (*MSX1, MTHFR, IRF6, PVRL1, SUMO1, BMP4* in addition to the previous list) have been reported in CLP.^[@R12]--[@R15]^ Among these genes, *MTHFR* is a disease gene with high-penetrance mutations.

Over the last few years, impaired *MTHFR* has been widely investigated to establish its potential role as a risk factor or marker of cardiovascular disease, neural tube defect, maxillofacial malformation, cognitive disorders, and cancer.^[@R16]--[@R21]^ Abnormal folate metabolism has been previously described as a possible risk factor for TOF.^[@R6]^ It has been hypothesized that genetic polymorphisms in folate-metabolizing enzymes affect global DNA methylation as well as changes the synthesis and repair of DNA. Furthermore, animal experiments have shown that disruption of the *MTHFR* gene results in decreased methylation capacity.^[@R22]^ There are, however, no reports about mutations on the *MTHFR* gene in TOF with CLP.

By contrast, this study found a novel *MTHFR* mutation (c.G586A, p.G196S) located in the functional region that may affect the enzyme activities. For the first time, levels of homocysteine in a patient with TOF and CLP were shown to be affected by the mutation using targeted, next-generation sequencing, which mutation had not been described in any previous reports or databases. The physiological function of *MTHFR* gene is changed by the mutation, a defect that leads to methionine deficiency and over-accumulation of homocysteine, in turn which leads to lowered *MTHFR* enzymatic activity or lowered folate levels. As the result of reduced enzymatic activity and elevated plasma homocysteine levels, the patient may exhibit congenital malformations (tetralogy of Fallot, plus cleft lip, and palate). Our study broadens the mutation spectrum of the *MTHFR* gene and suggests that this approach will facilitate etiological elucidation of this congenital malformation, which causes TOF and CLP, by effective identification of the causative genetic mutations.

In spite of this study has found a new mutation by the new research method, but there are still some shortcomings in this study. On the one hand, the sample size is not enough. On the other hand, this research has not carried out further functional studies on the new mutation found such as zebra fish or mouse.

CONCLUSIONS
===========

Using targeted, next-generation sequencing technology, we identified for the first time a mutation (c.G586A, p.G196S) in the *MTHFR* gene as a possible cause of TOF and CLP in a patient. Due to the complex and long cycle of treatment procedures for CHD and CLP, these diseases can bring a heavy burden to family and society and seriously affect neonatal health. It becomes urgent to reduce the birth rate of children with CHD and CLP by screening of the pathogenic genes and avoid surgical treatment by gene therapy in Chinese rural areas.
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###### 

The Results of Targeted Sequencing

  Category                             
  ------------------------------------ ------
  The total number of mutations        1520
   The number of SNP                   1390
   The number of missing mutations     82
   The number of insertion mutations   48
  Database of dbSNP                    515
  Database of TGP                      173
  Database of YH                       46
  Database of ESP                      6

dbSNP, Single Nucleotide Polymorphism Database; ESP, Exome Sequencing Project; TGP, 1000 Genomes Project; YH, Yan Huang.

###### 

The Results of Prediction

  Genes      Chromosome   SIFT        PolyPhen 2          Mutation Taster   CCDS     Amino Acid
  ---------- ------------ ----------- ------------------- ----------------- -------- ------------
  *ZNF528*   Chr19        Tolerated   Benign              Polymorphism      A598G    S200G
  *PVRL2*    Chr19        Tolerated   Benign              Polymorphism      C214G    R72G
  *MTHFR*    Chr1         Damaging    Probably damaging   Disease causing   G586A    G196S
  *EVC2*     Chr4         Tolerated   Benign              Polymorphism      G2623A   V875I
  *DAND5*    Chr19        Tolerated   Possibly damaging   Disease causing   G515A    R172Q
  *CCDC39*   Chr3         Tolerated   Benign              Polymorphism      G1035T   R345S

CCDS, the consensus coding sequence; *MTHFR*, methylenetetrahydrofolate reductase.
